Inhibition Of Prostanoid Receptor EP2: A Novel Anti-inflammatory Therapy For Chronic Neurodegenerative And Autoimmune Diseases | 10531
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Inflammation is a key driver of many chronic central nervous system and peripheral diseases. While COX-2 inhibitors proved to
be efficacious in reducing the pain and severity of the disease in patients with arthritis, they have not provided any benefit to the
patients with neurodegenerative diseases such as Alzheimer?s and epilepsy. Recently two clinically used COX-2 drugs, Vioxx? and
Bextra?, have been withdrawn from the United States market due to cardiovascular side effects, raising the limitation on future
use of the COX-2 inhibitors. Studies have confirmed that the side effects by the COX-2 drugs are due to blocking of the prostanoid
receptor IP, downstream of COX-2 enzyme. The IP receptor functions as a cardioprotective agent and prevents hypertension,
stoke and atherosclerosis. Thus future anti-inflammatory therapy should be mediated through a specific pro-inflammatory
prostanoid receptor. The EP2 receptor is emerging as a pro-inflammatory target in variety of chronic neurodegenerative and
peripheral disease models. We have recently identified a novel class of EP2 antagonists and by medicinal chemistry we have
developed a lead compound with requisite plasma and brain pharmacokinetics. We also demonstrated that this compound is able
to blunt the inflammation and neurodegeneration in a mouse model of status epilepticus (epilepsy). This lecture will provide an
overview on EP2 antagonism as an alternative anti-inflammatory approach in comparison to COX-2 inhibition.
Thota Ganesh completed his Ph.D. from Osmania University, India in 1999, then he did postdoctoral work at University of Durham, UK, and then
in laboratory of David G. I. Kingston at Virginia Tech. He joined Emory Chemical Biology Discovery Center as senior scientist, and he was recently
promoted to an Assistant Professor at the Department of Pharmacology, Emory University. He has published more than 40 publications in peer-
reviewed journals and 8-patents. His recent contributions include evaluation of bioactive conformation of anti-cancer agents Taxol and epothiolones,
development of small molecule inhibitors for Hsp90, histone methyltransferases, NADPH-oxidases (NOX) and EP2 receptor.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals